definit
fat
fpurin
explain
scheme
use
guanin
g
exampl
fat
purin
larg
ring
system
contain
imidazol
ring
fuse
varieti
nitrogen
heterocycl
amino
andor
carbonyl
function
group
thu
structur
regard
ringexpand
purin
ring
fusion
goe
beyond
system
inform
refer
super
fat
sf
purin
correspond
ringexpand
nucleosid
nucleotid
analogu
often
refer
ren
rent
fat
purin
nucleosid
nucleotid
analogu
chemic
biochem
biophys
medicin
interest
chemic
standpoint
synthesi
structur
stabil
acidbas
properti
aromat
tautomer
equilibria
worth
explor
biochem
perspect
abund
sourc
substrat
inhibitor
enzym
purin
metabol
well
requir
energi
cofactor
biophys
point
view
potenti
excel
probe
nucleic
acid
structur
function
metabol
medicin
stanc
prove
anticanc
antivir
agent
may
also
therapeut
use
exampl
fpurin
regard
analogu
extensivelyexplor
benzodiand
triazepin
famili
power
pharmaceut
act
central
nervou
system
concern
chemistri
number
fpurin
nucleosidenucleotid
analogu
ren
rent
prove
synthet
challeng
although
stabl
synthes
step
lead
synthesi
often
plagu
opportunist
rearrang
repeatedli
discov
year
also
experi
other
work
similar
area
sinc
larg
number
alleg
seven
larger
ring
heterocycl
later
found
system
refer
cite
therein
therefor
structur
must
assign
due
caution
prefer
singlecryst
xray
diffract
analys
unequivoc
synthes
extens
spectroscop
analysi
secondli
presenc
sever
n
atom
heterocycl
ring
make
difficult
predict
plan
specif
site
glycosyl
priori
normal
one
regioisom
obtain
synthes
analogu
often
complic
format
regioisom
theoret
signific
fpurin
concern
novel
physicochem
properti
includ
aromat
thermodynam
stabil
reactiv
acidbas
properti
tautomer
equilibria
biochem
structur
similar
natur
counterpart
fpurin
nucleosidetid
analogu
ren
rent
potenti
rich
sourc
substrat
inhibitor
enzym
purin
metabol
enzym
requir
energi
cofactor
gtp
atp
import
preced
potenti
substrateinhibitori
activ
ringexpand
nucleosid
provid
natur
form
three
naturallyoccur
antitumor
antibiot
coformycin
pentostatin
contain
imidazo
diazepin
ring
system
strongest
known
inhibitor
adenosin
deaminas
ada
azepinomycin
nonnucleosid
contain
imidazo
diazepin
ring
skeleton
report
inhibit
guanin
deaminas
guanas
scheme
three
antibiot
possess
tetrahedr
geometri
hydroxyl
junction
sevenmemb
ring
henc
regard
transit
state
analogu
inhibitor
ada
guanas
surprisingli
major
work
done
other
area
target
either
coformycin
synthet
analogu
except
contrast
ren
rent
studi
author
laboratori
cover
broad
rang
planar
pucker
molecul
potenti
act
substrat
andor
inhibitor
wide
varieti
enzym
purin
metabol
besid
ada
guanas
biophys
nucleotid
incorpor
steric
bulk
skeleta
compar
natur
counterpart
offer
uniqu
mean
explor
steric
conform
constraint
format
nucleic
acid
doubl
helic
steric
bulk
often
associ
consider
structur
deviat
natur
array
replac
natur
nucleotid
ringexpand
nucleotid
rent
affect
basepair
stack
interact
nucleic
acid
would
consequ
impact
upon
helic
structur
stabil
conform
singleand
doublestrand
rna
dna
helic
biophys
studi
employ
rent
aid
understand
better
factor
paramet
govern
format
structur
stabil
nucleic
acid
doubl
helic
furthermor
uniqu
geometr
featur
coupl
novel
electron
ioniz
conform
characterist
rent
also
potenti
excel
probe
nucleic
acid
tripl
helic
therefor
studi
primari
secondari
structur
ren
rent
polynucleotid
deriv
interest
import
investig
primari
structur
properti
includ
topolog
tautomer
acidbas
properti
aromat
etc
heterocycl
ring
synanti
baseribos
conform
endoexo
sugar
pucker
configur
etc
nucleosid
investig
secondari
structur
includ
helic
format
stabil
conform
polynucleotid
compos
rent
potenti
form
doubl
helic
complementari
basepair
appropri
pyrimidin
partner
vertic
stack
interact
secondari
structur
nucleic
acid
larg
part
govern
primari
structur
compon
nucleotid
medicin
signific
fpurin
ren
rent
root
structur
similar
natur
purin
vast
major
prove
anticanc
antivir
agent
search
molecular
basi
broad
spectrum
biolog
activ
perform
molecular
model
studi
inde
provid
interest
mechanist
notion
figur
shown
figur
watsoncrick
basepair
array
repres
ren
contain
fg
base
shown
magenta
molecular
model
studi
perform
use
quantacharmm
avail
accelri
softwar
inc
san
diego
extens
energi
minim
carri
two
duplex
employ
adopt
basi
newtonraphson
abnr
protocol
point
converg
rm
gradient
basepair
natur
c
cytosin
shown
yellow
comparison
fg
c
pair
superimpos
natur
g
c
pair
shown
yellow
seen
fg
c
favor
basepair
array
reason
compar
natur
counterpart
conspicu
differ
exist
one
consider
deviat
basesugar
bond
fg
g
shown
arrow
second
angl
compris
basesugar
bond
fg
anomer
carbon
c
doubl
helix
oppos
typic
valu
natur
bdna
doubl
helix
third
interstrand
distanc
r
fg
c
pair
contrast
typic
r
valu
bdna
duplex
signific
deviat
r
natur
array
would
dire
consequ
duplex
stabil
nucleic
acid
order
explor
possibl
molecular
model
built
heterooligom
duplex
contain
natur
nucleotid
pair
random
sequenc
form
bdna
figur
left
compar
contrast
anoth
copi
bdna
built
keep
nucleotid
basepair
origin
bdna
sequenc
replac
g
fg
posit
complementari
strand
extens
energi
minim
perform
two
duplex
reveal
incorpor
fg
dna
caus
consider
distort
doubl
helix
sever
disrupt
basepair
hydrogen
bond
ultim
lead
unzip
doublehelix
start
deviant
fg
residu
figur
right
implic
incorpor
fg
grow
dna
chain
transcript
revers
transcript
would
potenti
hinder
incorpor
subsequ
nucleotid
b
caus
basepair
disrupt
mismatch
frameshift
andor
c
prevent
format
caus
distort
doubl
helix
one
combin
factor
would
lead
inhibit
viral
tumor
replic
irrespect
biolog
signific
ren
rent
offer
import
platform
explor
fundament
scientif
principl
pertain
nucleic
acid
structur
format
stabil
function
exampl
would
great
interest
explor
enough
flexibl
doublehelix
accommod
structur
deviat
aris
aberr
basepair
array
increas
crosssect
width
rent
would
incorpor
nucleotid
increas
stabil
doublehelix
extent
would
increas
surfac
area
rent
enhanc
intrastrand
stack
interact
sinc
vertic
stack
interact
wide
believ
overrid
complementari
basepair
interact
respect
contribut
toward
doubl
helic
stabil
would
appropri
rentbas
nucleic
acid
stabl
natur
investig
would
highli
interest
reward
mention
earlier
synthesi
fpurin
often
pose
synthet
challeng
especi
potenti
antiaromat
rule
may
prefer
form
aromat
system
antiaromat
even
form
often
prone
easi
opportunist
rearrang
ringtransform
form
either
ring
specif
exampl
provid
scheme
show
attempt
synthesi
intend
fat
adenin
fa
target
yield
n
hydrazinopurin
structur
confirm
unequivoc
synthesi
reaction
hydrazin
order
avoid
undesir
ringclosur
intermedi
form
instead
scheme
prepar
nmethyl
deriv
use
methylhydrazin
scheme
two
isom
obtain
separ
ringclosur
attempt
use
trifluoroacet
acid
catalyst
methanol
product
obtain
unfus
ring
system
instead
desir
structur
confirm
unequivoc
synthesi
scheme
involv
initi
demethyl
form
use
boron
tribromid
follow
ringclosur
trimethyl
orthoform
form
latter
ident
product
obtain
ringclosur
trimethyl
orthoform
tent
mechan
format
outlin
scheme
analogu
broadspectrum
therapeut
molecular
model
studi
biosyminsight
iidiscov
avail
accelri
softwar
inc
san
diego
reveal
target
exist
essenti
planar
structur
slight
deviat
planar
ring
nh
suggest
compound
antiaromat
rule
electron
furthermor
energi
calcul
show
introduct
one
two
carbonyl
group
ring
would
consider
enhanc
stabil
system
thu
calcul
energi
increas
order
adenin
analogu
guanin
analogu
xanthin
analogu
scheme
encourag
result
undertook
synthesi
scheme
howev
precursor
yield
desir
final
product
instead
form
anoth
imidazolyl
oxadiazepinon
problem
ultim
solv
synthes
scheme
remov
benzyl
group
prevent
undesir
ringclosur
latter
form
intermedi
upon
treatment
sodium
methoxid
methanol
final
benzyl
protect
group
remov
heat
aluminum
chlorid
toluen
yield
parent
imidazo
compound
highli
stabl
solid
consider
aqueou
solubl
littl
solubl
organ
solvent
light
observ
stabil
consist
energi
calcul
describ
earlier
sought
synthes
complet
aromat
planar
fpurin
analogu
introduct
appropri
number
amino
imino
andor
carbonyl
group
ring
heterocycl
two
compound
interest
regard
triaminoand
monoaminodicarbonyl
compound
respect
contain
imidazo
diazepin
ring
system
scheme
conveni
synthes
onestep
condens
correspond
dimethoxycarbonyl
deriv
guanidin
structur
confirm
singlecryst
xray
diffract
analysi
well
nlabel
studi
stabl
solid
unlik
planar
potenti
antiaromat
system
describ
earlier
synthesi
nonplanar
nonaromat
system
rel
easier
order
avoid
undesir
degrad
deem
necessari
protect
free
sidechain
nh
remov
protect
group
thu
benzyl
deriv
prepar
scheme
treat
sodium
hydrid
dmso
result
undesir
rearrang
form
xanthin
deriv
structur
confirm
singlecryst
xray
diffract
analysi
tent
mechan
format
outlin
scheme
final
desir
success
obtain
albeit
low
yield
replac
sidechain
methoxycarbonyl
group
highli
reactiv
pnitrophenoxycarbonyl
group
follow
ringclosur
mild
basic
condit
scheme
compound
stabl
yellow
solid
structur
consist
spectroscop
analyt
data
coformycin
analogu
call
pentostatin
two
natur
antitumor
compound
strongest
known
inhibitor
adenosin
deaminas
ada
k
rang
despit
highli
potent
ada
inhibitori
activ
clinic
success
anticip
grant
benefit
use
pentostatin
treatment
leukemia
lymphoma
particular
acut
lymphocyt
leukemia
hairi
cell
leukemia
notabl
sever
toxic
limit
effect
use
broadspectrum
therapeut
wide
believ
basi
toxic
prolong
extrem
tightbind
nearli
irrevers
inhibit
ada
essenti
metabol
enzym
coformycin
pentostatin
mimic
transit
state
enzymecatalyz
reaction
thu
necessit
synthesi
new
enzym
molecul
time
recoveri
toxic
effect
therefor
desir
ada
inhibitor
somewhat
less
tightbind
easili
revers
still
highli
potent
shorter
durat
action
faster
enzym
recoveri
effort
find
inhibitor
care
examin
report
xray
crystal
structur
complex
ada
pentostatin
also
call
dcf
figur
reveal
tightbind
characterist
aris
multipl
hydrogen
bond
sugar
hydroxyl
amino
acid
residu
protein
coupl
coordin
bond
heterocycl
group
activ
site
zinc
ion
notabl
featur
crystal
structur
observ
anti
sugar
conform
sugar
orient
away
heterocycl
ring
suggest
us
conform
forc
predomin
syn
orient
sugar
face
ring
anticip
intramolecular
hydrogen
bond
sugar
heterocycl
shown
hydrogen
bond
observ
anti
orient
would
lost
addit
perhap
weaken
coordin
bond
zinc
ion
thu
lead
less
tightbind
easili
revers
inhibit
characterist
high
syn
orient
confirm
crystal
state
xray
solut
noe
studi
relat
ringexpand
nucleosid
analogu
contain
imidazo
diazepin
observ
larg
noe
imidazol
ring
sugar
moieti
synthesi
outlin
scheme
corrobor
predominantli
syn
orient
solut
inde
test
inhibitori
activ
ada
calf
intestin
mucosa
exhibit
k
x
sever
order
magnitud
lower
activ
coformycin
anticip
furthermor
nucleosid
lack
crucial
group
form
coordin
bond
activ
site
zinc
complet
devoid
activ
support
signific
enzym
bind
effort
underway
optim
inhibit
potenc
still
maintain
semitight
bind
characterist
revers
enzym
inhibit
properti
guanin
deaminas
gda
guanas
ec
enzym
catalyz
hydrolyt
deamin
guanin
xanthin
enzym
found
human
liver
brain
kidney
report
abnorm
high
level
serum
guanas
activ
patient
liver
diseas
elev
enzym
activ
suggest
marker
hepat
hepatoma
furthermor
high
guanas
activ
believ
biochem
indic
reject
liver
transplant
recipi
increas
level
guanas
also
detect
cancer
kidney
breast
cancer
tissu
addit
patient
multipl
sclerosi
exhibit
significantli
elev
level
guanas
activ
cerebr
spinal
fluid
observ
suggest
potent
guanas
inhibitor
necessari
explor
biochem
mechan
metabol
disord
well
understand
specif
physiolog
role
play
guanas
mention
potenti
therapeut
use
treat
disord
mani
studi
guanas
inhibit
report
literatur
includ
potent
guanas
inhibitor
submicromolar
k
yet
realiz
guanas
catalyz
hydrolysi
guanin
xanthin
scheme
via
tetrahedr
intermedi
scheme
xray
crystal
structur
gda
bacillu
subtili
suggest
enzymecatalyz
reaction
assist
activ
site
zinc
ion
zn
ada
lead
specul
known
gda
inhibitor
azepinomycin
may
act
like
transit
state
mimic
coformycin
case
ada
inhibit
describ
earlier
howev
moder
inhibit
guanas
report
suggest
somewhat
weaker
bind
inhibitor
enzym
via
zinc
metal
coordin
hypothes
might
due
possibl
facil
elimin
crucial
oh
group
water
assist
anchimer
ring
nh
group
therefor
move
oh
group
one
carbon
away
ring
would
allevi
problem
hypothes
introduct
carbonyl
group
heterocycl
coupl
presenc
hydroxymethyl
group
would
allow
excel
coordin
inhibitor
zn
form
stabl
ring
structur
shown
latter
would
use
two
four
metal
coordin
site
two
would
occupi
two
three
origin
amino
acid
residu
enzym
activ
site
rational
synthes
scheme
start
target
along
screen
rabbit
liver
guanas
found
possess
k
valu
x
x
respect
valu
roughli
compar
report
ic
valu
x
azepinomycin
sar
studi
current
progress
order
enhanc
potenc
without
compromis
revers
enzym
bind
characterist
compound
planar
aromat
heterocycl
interest
explor
tautomer
equilibria
especi
convert
nucleosid
analogu
one
three
amino
group
would
necessarili
exist
imino
function
depend
upon
one
three
amino
group
would
assum
imino
structur
nucleosid
analogu
scheme
mimic
adenosin
guanosin
isoguanosin
resolv
issu
label
three
nitrogen
atom
guanidin
n
carri
condens
obtain
tripli
label
latter
upon
standard
ribosyl
provid
tripli
label
n
nmr
show
two
singlet
ppm
correspond
two
label
ring
nitrogen
atom
one
triplet
j
nh
hz
region
correspond
label
exonuclear
nh
group
suggest
molecul
exist
equilibrium
mixtur
two
never
possibl
exist
adenosineand
guanosinelik
tautom
solut
gave
rise
notion
might
possibl
design
inhibitor
could
simultan
inhibit
ada
gda
import
differ
substrat
requir
two
enzym
need
reconcil
natur
substrat
ada
nucleosid
adenosin
gda
heterocycl
base
guanin
order
circumv
problem
decid
attach
acycl
sugar
moieti
synthesi
acycl
nucleosid
outlin
scheme
nucleosid
acycl
nucleosid
bichem
assay
ada
gda
anticip
nucleosid
found
competit
inhibitor
ada
k
x
gda
wherea
acycl
nucleosid
found
competit
inhibitor
ada
k
x
gda
k
x
analogu
broadspectrum
therapeut
polynucleotid
phosphorylas
e
coli
primerindepend
polymeras
convert
nucleosid
correspond
homopolym
presenc
mn
requir
primer
obvious
attract
enzym
synthesi
fat
polym
ringexpand
nucleotid
explor
fundament
biophys
properti
nucleic
acid
particular
spatial
conform
constraint
format
nucleic
acid
doubl
helic
well
factor
govern
helic
structur
stabil
conform
also
light
longsuspect
correl
conform
properti
nucleosid
observ
biolog
activ
systemat
studi
continu
warrant
explor
littl
understood
interrelationship
nucleosid
basesugar
conform
sugar
pucker
eas
vivo
phosphoryl
enzym
polymer
biolog
activ
end
synthes
two
ringexpand
nucleosid
ren
analogu
contain
imidazo
diazepin
ring
system
scheme
heterocycl
base
ren
anticip
nonplanar
nonaromat
opposit
basesugar
conform
syn
anti
thu
consid
good
probe
intend
biophys
evalu
two
target
nucleosid
screen
murin
leukemia
viru
mulv
tissu
cultur
system
show
potent
antivir
activ
ic
inhibitori
concentr
compound
requir
reduc
viral
pathogen
micromolar
rang
total
devoid
activ
interest
biolog
result
elev
interest
biophys
properti
isomer
nucleosid
analogu
singlecryst
xray
structur
analysi
two
nucleosid
figur
reveal
sugar
exist
syn
orient
dictat
strong
hydrogen
bond
bottom
nh
ring
sugar
ring
sugar
orient
anti
led
specul
compound
exist
prefer
conform
solut
would
less
prone
phosphoryl
vivo
sinc
kinas
enzym
respons
vivo
phosphoryl
nucleosid
nucleotid
known
prefer
anti
orient
actual
reactiv
speci
vivo
nucleotid
would
explain
differ
observ
biolog
activ
two
nucleosid
attempt
throw
light
subject
first
investig
solut
conform
two
ren
use
h
nmrbase
nuclear
overhaus
effect
noe
circular
dichroism
studi
observ
noe
imidazol
sugar
suggest
highli
syn
basesugar
conform
consist
anti
conform
favor
kinas
analogu
broadspectrum
therapeut
confirm
synanti
conform
inde
play
role
observ
biolog
activ
decid
elimin
hbond
respons
syn
conform
synthes
n
deriv
anticip
bulki
methyl
group
would
remov
hbond
would
also
forc
conform
becom
predominantli
anti
synthesi
n
methyl
deriv
outlin
scheme
inde
assay
mulv
antivir
activ
even
slightli
better
thu
corrobor
specul
correl
conform
biolog
activ
proceed
evalu
differ
conform
featur
nucleic
acid
homopolym
deriv
two
isomer
ren
end
chemic
synthes
necessari
deriv
employ
standard
phosphoryl
procedur
subject
ren
diphosph
polymer
ecoli
polynucleotid
phosphorylas
presenc
mn
form
correspond
homopolym
poli
poli
scheme
diphosph
found
substrat
enzym
although
yield
homopolym
obtain
syn
isom
nearli
less
anti
isom
extent
polymer
determin
assess
inorgan
phosphat
releas
polymer
reaction
b
uv
absorb
extens
dialyz
product
c
determin
length
homopolym
gel
electrophoresi
indic
polymer
rang
secondari
structur
homopolym
determin
uv
cd
spectral
measur
consider
hyperchrom
effect
observ
upon
increas
temperatur
homopolym
poli
obtain
anti
isom
suggest
possess
signific
secondari
structur
presenc
stoichiometr
amount
spermin
cation
charg
homopolym
display
broad
absorbancetemperatur
profil
hyperchrom
suggest
presenc
intrastrand
secondari
structur
contrast
result
obtain
homopolym
poli
obtain
syn
isom
gave
littl
indic
secondari
structur
without
spermin
even
spermin
observ
tm
hyperchrom
less
consider
lower
poli
cd
spectra
two
homopolym
corrobor
find
exhibit
signific
cotton
effect
poli
analogu
broadspectrum
therapeut
maximum
nm
crossov
minimum
nm
upon
addit
stoichiometr
level
spermin
chang
spectrum
doubl
absolut
valu
minimum
suggest
helic
structur
contrast
poli
exhibit
neither
cotton
effect
notic
spectral
perturb
upon
addit
spermin
tabl
tabl
antivir
activ
repres
ren
ec
effect
concentr
compound
reduc
viral
pathogen
siselect
indexratio
cytotox
concentr
compound
kill
normal
cell
requir
kill
viral
cell
ren
also
exhibit
potent
vitro
anticanc
activ
differ
human
tumor
cell
line
list
tabl
ii
includ
limit
tumor
breast
lung
prostat
colon
kidney
cn
skin
ovari
leukemia
view
observ
broad
spectrum
antivir
anticanc
activ
ren
list
tabl
explor
mechan
biolog
activ
becam
instant
interest
end
decid
focu
import
virus
cancer
use
repres
ren
mechanist
effort
cancer
area
predominantli
involv
breast
prostat
cancer
lead
caus
cancer
mortal
american
femal
male
respect
mechanist
investig
viral
area
mainli
target
flavi
virus
includ
hepat
c
hcv
west
nile
wnv
japanes
enceph
jev
virus
extent
hepat
b
hbv
human
immunodefici
hiv
virus
virus
current
global
health
prioriti
regard
prostat
cancer
explor
vitro
biolog
effect
ren
latter
perceiv
prodrug
former
see
tabl
two
androgenindepend
human
prostat
cancer
cell
line
studi
concentr
explor
dosedepend
induct
apoptosi
program
cell
death
treat
cancer
cell
dose
respons
profil
cytotox
effect
nucleosid
human
prostat
cancer
cell
investig
specif
cell
treat
increas
concentr
day
cell
viabil
determin
use
trypan
blue
exclus
assay
result
case
indic
treatment
exponenti
grow
cultur
cell
two
day
lead
mark
loss
cell
viabil
dosedepend
manner
investig
time
cours
cytotox
androgenindepend
prostat
cancer
cell
day
treatment
cell
concentr
cell
kill
observ
attempt
understand
potent
antibreast
cancer
activ
ren
cell
see
tabl
discov
compound
stop
cell
prolifer
seemingli
reduc
cell
number
treat
cultur
perform
mechanist
studi
use
prodrug
found
compound
significantli
decreas
rna
dna
synthesi
cell
see
figur
strongli
inhibit
cell
prolifer
wherea
cell
growth
assay
demonstr
slightli
decreas
cell
number
incub
either
hour
compound
decreas
equival
observ
cell
incub
ic
concentr
arac
regardless
exposur
time
combin
arac
enhanc
cell
kill
suggest
arac
act
mechanist
pathway
observ
inhibit
rna
dna
synthesi
ren
point
intrigu
possibl
mechan
action
includ
limit
could
phosphoryl
vivo
kinas
deriv
subsequ
incorpor
nucleic
acid
transcript
dnarna
templat
polymeras
caus
doublehel
distort
ultim
lead
chain
termin
b
could
bind
activ
alloster
site
polymeras
either
nucleosid
nucleotid
caus
competit
noncompetit
inhibit
order
throw
light
subject
chemic
convert
reactiv
speci
vivo
deriv
scheme
biochem
screen
inhibit
nucleic
acid
polymeras
activ
employ
synthet
dna
oligonucleotid
templat
bacteriophag
rna
polymeras
repres
polymeras
result
suggest
moder
inhibitor
rna
polymeras
moieti
appear
essenti
inhibit
nucleosid
alon
fail
inhibit
polymeras
reaction
mechanist
explor
viral
field
larg
focus
flavivirida
includ
hcv
wnv
jev
discov
mechan
action
famili
virus
involv
inhibit
viral
ntpasehelicas
helicas
respons
unwind
duplex
rna
dna
structur
disrupt
hydrogen
bond
keep
two
strand
togeth
process
depend
upon
necessari
energi
releas
hydrolysi
molecul
ntp
atp
gtp
studi
point
exist
alloster
bind
site
viral
ntpaseshelicas
occupi
nucleosidenucleotidetyp
molecul
ren
inhibit
viral
helicas
activ
also
found
low
atp
concentr
bind
enzym
ntp
bind
site
competit
inhibit
viral
ntpase
activ
exampl
atp
concentr
equal
x
k
valu
enzym
rentriphosph
inhibit
wnv
ntpase
reaction
ic
valu
recent
discov
number
ren
inhibit
hiv
hcv
lead
ren
regard
see
tabl
contain
long
hydrophob
chain
heterocycl
ring
practic
wipe
hiv
replic
cell
monocytederiv
macrophag
micromolar
concentr
found
potent
inhibit
atp
depend
helicas
activ
human
rna
helicas
well
ntpasehelicas
activ
hcv
furthermor
neither
two
ren
exhibit
toxic
therapeut
dose
ex
vivo
cell
cultur
vivo
mice
dual
inhibit
hiv
hcv
ren
import
implic
treat
hiv
patient
infect
hcv
vast
major
patient
us
western
hemispher
ultim
die
liver
cirrhosi
liver
carcinoma
current
avail
separ
therapi
hiv
hcv
unfavor
drug
interact
lead
exacerb
hcv
hiv
therefor
drug
would
act
hcv
hiv
immin
need
dualact
ren
good
prospect
regard
ren
found
potent
select
inhibitor
replic
hepat
b
viru
hbv
cultur
human
hepatoblastoma
cell
activ
ren
inhibit
synthesi
intracellular
hbv
replic
intermedi
extracellular
virion
releas
effect
concentr
ec
respect
select
indic
respect
toxic
three
compound
also
measur
rapidli
grow
human
foreskin
fibroblast
hff
cell
daudi
cell
cell
prolifer
assay
neglig
toxic
observ
cell
also
interest
note
three
ren
unlik
industri
standard
use
antihbv
activ
result
reduct
viral
protein
synthesi
especi
core
antigen
ringexpand
heterocycl
nucleosid
nucleotid
possess
excel
promis
broadspectrum
therapeut
cancer
virus
promis
vitro
data
particularli
prostat
breast
cancer
virus
particular
hbv
hcv
analogu
broadspectrum
therapeut
